# Metformin Versus Vildagliptin for Diabetic Hypertensive Patients

Study · id `cardio:ct-nct03253562` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03253562](<https://clinicaltrials.gov/study/NCT03253562>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03253562

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT03253562. Randomized; single masking; primary purpose treatment. Start 2017-02-01 (actual); primary completion 2017-08-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT03253562, source copy `cardio:ctgov-nct03253562-2017-08-18`, retrieved 2026-10-26)
- Started: 2017-02-01 (actual) (ClinicalTrials.gov record NCT03253562, source copy `cardio:ctgov-nct03253562-2017-08-18`, retrieved 2026-10-26)
- Primary completion: 2017-08-01 (actual) (ClinicalTrials.gov record NCT03253562, source copy `cardio:ctgov-nct03253562-2017-08-18`, retrieved 2026-10-26)
- Completion: 2017-08-01 (actual) (ClinicalTrials.gov record NCT03253562, source copy `cardio:ctgov-nct03253562-2017-08-18`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT03253562, source copy `cardio:ctgov-nct03253562-2017-08-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03253562-2017-08-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Metformin Versus Vildagliptin for Diabetic Hypertensive Patients
- Condition: Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients
- Intervention (Drug): Metformin Pill
- Intervention (Drug): Vildagliptin 50 mg
- Lead sponsor: MTI University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: da92a8fcce77cbc9c92471fa123c85ef5dbd0a38f1c019c7d91314f511232b58
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
